Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Insulin: Dosing Regimen and Adverse Effects

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...

Insulin: Biosynthesis, Chemistry, and Preparation

Insulin: Biosynthesis, Chemistry, and Preparation

The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...

Insulin Formulations: Types and Delivery

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...

Diabetes: Management and Pharmacotherapy

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Prematriculation Programs for Student Pharmacist Success.

American journal of pharmaceutical education·2025

Same author

State of the Academy-Challenges to Student Success.

American journal of pharmaceutical education·2025

Same author

Envisioning the Future of Student Success: Report of the 2022-2023 AACP Student Affairs Standing Committee.

American journal of pharmaceutical education·2023

Same author

An Evaluation of Nonacademic Predictors of Success in a Doctor of Pharmacy Program.

American journal of pharmaceutical education·2022

Same author

Low-Molecular-Weight Heparin Prophylaxis Dosing: Is Weight an Issue?

The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians·2021

Same author

Assessment of a didactic ambulatory care pharmacy elective on student perceptions and subsequent performance in an ambulatory care advanced pharmacy practice experience.

Currents in pharmacy teaching & learning·2018

Search research articles

Related Experiment Video

Updated: May 28, 2026

Improving IV Insulin Administration in a Community Hospital

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Removing barriers to insulin use.

Molly G Minze¹, Kavita Dalal, Brian K Irons

¹School of Pharmacy, Texas Tech University Health Sciences Center, Abilene, TX, USA. molly.minze@ttuhsc.edu

The Journal of Family Practice

|October 7, 2011

Summary

This summary is machine-generated.

Physicians and patients often resist insulin therapy for type 2 diabetes, despite its proven benefits. This guide helps overcome psychological "insulin resistance" to improve treatment adherence.

More Related Videos

Assessing Insulin Clearance in Mice via In Situ Liver Perfusion

Assessing Insulin Clearance in Mice via In Situ Liver Perfusion

Published on: December 13, 2024

Related Experiment Videos

Last Updated: May 28, 2026

Improving IV Insulin Administration in a Community Hospital

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Assessing Insulin Clearance in Mice via In Situ Liver Perfusion

Assessing Insulin Clearance in Mice via In Situ Liver Perfusion

Published on: December 13, 2024

Area of Science:

Endocrinology
Metabolic Disorders
Diabetes Management

Background:

Type 2 diabetes is a progressive metabolic disorder.
Insulin therapy is highly effective but underutilized.
Patient and physician reluctance presents a significant barrier to optimal glycemic control.

Purpose of the Study:

To explore the reasons behind the reluctance to initiate insulin therapy in type 2 diabetes.
To provide strategies for overcoming psychological and practical barriers to insulin treatment.
To improve patient outcomes through enhanced insulin therapy adoption.

Main Methods:

Literature review on barriers to insulin therapy.
Analysis of patient and physician perspectives.
Development of a framework for addressing "insulin resistance" to treatment.

Main Results:

Common barriers include fear of hypoglycemia, weight gain, and perceived treatment failure.
Physician-related factors include time constraints and educational gaps.
Patient education and shared decision-making are crucial for successful initiation.

Conclusions:

Addressing psychological "insulin resistance" is key to increasing insulin adoption.
Effective communication and tailored strategies can overcome patient and physician hesitancy.
Optimizing insulin use improves long-term type 2 diabetes management and patient well-being.